Special Guest Seminar - Alison Goate

Human Genetics implicates efferocytosis in Alzheimer’s disease risk

Special Guest Seminar Header

As part of our virtual 'Special Guest Seminars' series, the UK DRI is delighted to welcome Prof Alison Goate.

"Human Genetics implicates efferocytosis in Alzheimer’s disease risk"

Tuesday 12 May, 14:00 - 15:00 BST

This event is open to UK DRI researchers and support staff only. Registration and associated Zoom links will be distributed via Centre Manager emails nearer the time of the event.


Prof Alison Goate  

Director, The Ronald M. Loeb Center for Alzheimer’s Disease 

Willard T.C. Johnson Research Professor of Neurogenetics 

Professor of Neuroscience, Neurology and Genetics & Genomic Sciences 

Icahn School of Medicine at Mount Sinai, New York, NY


Speaker Bio

Dr Alison Goate has worked on Alzheimer's disease genetics since 1987, when she joined Dr. John Hardy’s lab, as a postdoctoral fellow at Imperial College, London. In 1992 she moved to Washington University in St. Louis, where she stayed until 2014, when she moved to the Icahn School of Medicine at Mount Sinai as the founding director of the Ronald M. Loeb Center for Alzheimer’s disease. She has been part of many gene finding teams that have successfully identified disease causing variants for both AD and FTD. Whilst working with Dr Hardy she reported the first mutation to cause familial Alzheimer's disease and early studies at Washington University identified the mutation in the Colombian families that are now part of the API clinical trial. Her lab was also part of the team that first reported MAPT mutations in FTD. She has had a longstanding interest in the pathogenic mechanisms underlying MAPT mutations in FTD and MAPT haplotypic variation in risk for a range of neurodegenerative diseases including Progressive Supranuclear Palsy (PSP), Parkinson’s disease and AD.

Dr Goate is also a leader in the study of late onset AD genetics using both GWAS and sequencing approaches. She has demonstrated that LOAD families can carry PSEN mutations with reduced penetrance. Her team led the identification of rare variants in PLD3 as a risk factor for AD and collaborated with John Hardy in the identification of Trem2 as an AD risk factor. More recently her work on common variants has highlighted the importance of microglial expressed genes in AD risk, identifying SPI1/Pu.1 as an important regulator of AD risk genes. Fine mapping of AD risk loci has identified causal genes/variants in many loci and further emphasized the importance of microglial gene expression and function to AD risk. Dr Goate has received the Potamkin Award, the Khalid Iqbal Lifetime Achievement Award from the Alzheimer’s Association and the MetLife Award for her research on AD. She was elected a fellow of AAAS in 2012 and a fellow of the National Academy of Medicine in 2016.

Founding funders

Latest tweets from @UKDRI

RT @dr_menzies: Are you interested in a PhD in small molecule anti-compliment drug development? How about this one with Dr Zelek, Prof Morg…
23 May 2022 20:39

#ICYMI: Researchers led by Prof @isaacs_adrian (UK DRI at UCL) have developed a biomarker to track the success of t… https://t.co/ir92qxqfWE
23 May 2022 16:03